On 8 June 2021, EBC hosted a virtual Synthesis Meeting for the Value of Treatment 2 case study working groups to present their preliminary findings.

The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). EBC conceptualized in 2015 the Value of Treatment research framework with a first VOT study to address the increasing all-age burden of brain disorders–both neurological and mental alike.

Risk reduction, preclinical and early detection, and timely intervention are seen as the solutions to help national health systemsand society cope.In 2019, in order for the research to dig deeper into the current unmet needs in health care using a value-based approach, a second round (VOT2) on new therapeutic areas was launched; focusing on The Value of Early Coordinated Care for Rare Diseases (Ataxia, Dystonia and Phenylketonuria) and The Value of Early Intervention and Continuity of Care for Mental Disorders (Anorexia Nervosa, Autism Spectrum Disorderand Major Depressive Disorder).

Throughout 2020, joint working sessions aimed to exchange and build synergy between the research-work and the European Commission DG Sante Rare Diseases European Reference Networks (ERN-RNDand MetabERN) as well as the EU H2020 PECUNIA project on mental health services.

Moving towards the project’s last phase (Phase 3 “final results and publications”), EBC together with its members (EAN, EANS, ECNP, EFNA, EPA, EPNS, EUFAMI, FENS, GAMIAN Europe, IBRO) and experts who are participating in the research convened a meeting on 8 June 2021 to present a synthesis of the VOT2 research project results so far. The meeting brought together all experts from within VOT2 as well as external experts and a wider audience from the community. The experts presented their preliminary findings, which can be read in more detail in the full event report, downloadable below.

Both EBC position papers will be released on 7 December 2021 to be followed by scientific publications(Q1 2022). Beyond the research design and considering current context, the impact of Covid-19 on treatment and healthcare transformation will also be further explored.